Case Study: Strand Therapeutics shortens mRNA process development cycles with Benchling

Shortening mRNA process development cycles to build curative treatments for life-threatening diseases

Strand Therapeutics, a leader in mRNA therapeutics, needed a better way to capture and standardize process development data as it advanced curative treatments for cancer and other life-threatening diseases. The company moved from spreadsheets to Benchling to improve data management across its process development work.

With Benchling, Strand Therapeutics created a unified data model that linked process and analytical data, eliminated silos, and enabled high-throughput experiments on a centralized platform. This helped shorten process development cycles, improve data integrity, save time, and reduce costs, supporting major progress including FDA IND clearance for STX-001.

Strand Therapeutics

Mae Kingsbury

Associate Scientist II of mRNA Process Development